A Multi-center Study to Assess the Efficacy and Safety of LX211 in Active Non-infectious Anterior… (NCT00404885) | Clinical Trial Compass
CompletedPhase 3
A Multi-center Study to Assess the Efficacy and Safety of LX211 in Active Non-infectious Anterior Uveitis
United States108 participantsStarted 2007-01
Plain-language summary
The objective of this study is to evaluate the safety and efficacy of LX211 as therapy in subjects with active non-infectious anterior uveitis
Who can participate
Age range13 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Documented history of non-infectious anterior, anterior and intermediate- or panuveitis
* Currently uncontrolled uveitis for a minimum of 2 weeks despite use of oral and/or topical corticosteroid,or subjects who are intolerant of local corticosteroid therapy due to the development of an ocular hypertensive response or subjects for whom oral corticosteroid is contraindicated.
* Grade of 2+ or higher for anterior chamber cells at time of enrollment
* Considered by the investigator to require corticosteroid-sparing therapy.
* Subjects not planning to undergo elective ocular surgery during the study
Exclusion Criteria:
* Uveitis of infectious etiology
* Presence of an ocular toxoplasmosis scar
* An immune suppression regimen that includes an alkylating agent within the previous 90 days